Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
R&D channel feed
Scoop: AbbVie terminates early-stage study of I-Mab's antibody, another clinical setback in CD47 field
3 years ago
China
Updated: Small cannabinoid biotech says its CMO was hit with cyberattack, resulting in clinical trial delays
3 years ago
Keytruda hit with second PhIII setback this year as Merck's blockbuster flops certain head and neck trial
3 years ago
Bristol Myers vets tie up another all-stock deal, lining up clinical-stage oncology pipeline
3 years ago
Deals
Gene therapy for ovarian cancer fails PhIII study — sinking biotech's shares
3 years ago
Cell/Gene Tx
MDMA psychotherapy trial put on pause after Health Canada inspection
3 years ago
FDA+
Amgen, GSK, Regenxbio and others urge SCOTUS to review 'damaging' decision on biomedical patents
3 years ago
Law
As the pandemic high wanes, Inovio chops headcount again while chasing Covid win
3 years ago
People
Lynparza fails a PhIII test in colorectal cancer, cutting off big R&D avenue for Merck and AstraZeneca
3 years ago
Pharma
Editas hires top Sanofi scientist for CMO as C-suite shuffle continues
3 years ago
Sesen Bio pauses bladder cancer drug work, offloads eye disease antibodies to Roche
3 years ago
Eliem delays a depression trial, indefinitely postpones another after blaming CMC issues for low drug exposure
3 years ago
Kyowa Kirin pulls the plug on drug development for successor to Parkinson's drug Nourianz
3 years ago
As Big Pharma loses interest in new antibiotics, infections are only growing stronger
3 years ago
Texas biotech expands R&D and manufacturing capabilities following Catalent partnership
3 years ago
Manufacturing
Updated: ContraFect to terminate PhIII MRSA antibiotic trial — stock capsizes
3 years ago
Dark-horse ALS player touts open-label survival data after mid-stage flop, with platform study due soon
3 years ago
Novo Nordisk nabs priority review voucher for $110M from Marinus as the biotech preps first drug launch
3 years ago
Financing
Deals
With failed NIH Covid-19 study, Humanigen CEO points to competitors' flops before FDA nods
3 years ago
Coronavirus
Amazon joins Fred Hutch on clinical trial for personalized cancer vaccine — report
3 years ago
With eyes on Keytruda patent cliff, Merck takes a $290M swing at prostate cancer
3 years ago
Deals
Curtain-raiser data keep analysts on edge ahead of Amgen’s big Lumakras/PD-1 combo readout
3 years ago
Despite trial discontinuations, Rhythm’s genetic obesity drug effective in another rare indication
3 years ago
'Approvability has been put to bed': Aldeyra says eye drop clears three dry eye signals en route to FDA
3 years ago
First page
Previous page
127
128
129
130
131
132
133
Next page
Last page